Copper Recovery Originating from Galvanic Industry

Document(en) uit de collectie Chemische ProcestechnologieDelftChemTechApplied Science

Comparison of design rules for glued-in rods and design rule proposal for implementation in European standards

Structural EngineeringCivil Engineering and Geoscience

Widespread Frequent Methane Emissions From the Oil and Gas Industry in the Permian Basin

Emissions of methane (CH4) in the Permian basin (USA) have been derived for 2019 and 2020 from satellite observations of the Tropospheric Monitoring Instrument (TROPOMI) using the divergence method, in combination with a data driven method to estimate the background column densities. The resulting CH4 emission data, which have been verified using model data with known emissions, have a spatial resolution of approximately 10 km. The CH4 emissions show moderate spatial correlation with the locations of oil and gas production and drilling activities in the Permian basin, as well as with emissions of nitrogen oxides (NOx). Analysis of the emission maps and time series indicates that a significant fraction of methane emissions in the Permian basin is from frequent widespread emissions sources, rather than from a few infrequent very large unplanned releases, which is important considering possible CH4 emission mitigation strategies. In addition to providing spatially resolved emissions, the divergence method also provides the total emissions of the Permian basin and its main sub-basins. The total CH4 emission of the Permian is estimated as 3.0 ± 0.7 Tg yr−1 for 2019, which agrees with other independent estimates based on TROPOMI data. For the Delaware sub-basin, it is estimated as 1.4 ± 0.3 Tg yr−1 for 2019, and for the Midland sub-basin 1.2 ± 0.3 Tg yr−1. In 2020 the emissions are 9% lower compared to 2019 in the entire Permian basin, and respectively 19% and 27% for the Delaware and Midland sub-basins.Atmospheric Remote Sensin

Oxidoreductases on their way to industrial biotransformations

Fungi produce heme-containing peroxidases and peroxygenases, flavin-containing oxidases and dehydrogenases, and different copper-containing oxidoreductases involved in the biodegradation of lignin and other recalcitrant compounds. Heme peroxidases comprise the classical ligninolytic peroxidases and the new dye-decolorizing peroxidases, while heme peroxygenases belong to a still largely unexplored superfamily of heme-thiolate proteins. Nevertheless, basidiomycete unspecific peroxygenases have the highest biotechnological interest due to their ability to catalyze a variety of regio- and stereo-selective monooxygenation reactions with H2O2 as the source of oxygen and final electron acceptor. Flavo-oxidases are involved in both lignin and cellulose decay generating H2O2 that activates peroxidases and generates hydroxyl radical. The group of copper oxidoreductases also includes other H2O2 generating enzymes - copper-radical oxidases - together with classical laccases that are the oxidoreductases with the largest number of reported applications to date. However, the recently described lytic polysaccharide monooxygenases have attracted the highest attention among copper oxidoreductases, since they are capable of oxidatively breaking down crystalline cellulose, the disintegration of which is still a major bottleneck in lignocellulose biorefineries, along with lignin degradation. Interestingly, some flavin-containing dehydrogenases also play a key role in cellulose breakdown by directly/indirectly “fueling” electrons for polysaccharide monooxygenase activation. Many of the above oxidoreductases have been engineered, combining rational and computational design with directed evolution, to attain the selectivity, catalytic efficiency and stability properties required for their industrial utilization. Indeed, using ad hoc software and current computational capabilities, it is now possible to predict substrate access to the active site in biophysical simulations, and electron transfer efficiency in biochemical simulations, reducing in orders of magnitude the time of experimental work in oxidoreductase screening and engineering. What has been set out above is illustrated by a series of remarkable oxyfunctionalization and oxidation reactions developed in the frame of an intersectorial and multidisciplinary European RTD project. The optimized reactions include enzymatic synthesis of 1-naphthol, 25-hydroxyvitamin D3, drug metabolites, furandicarboxylic acid, indigo and other dyes, and conductive polyaniline, terminal oxygenation of alkanes, biomass delignification and lignin oxidation, among others. These successful case stories demonstrate the unexploited potential of oxidoreductases in medium and large-scale biotransformations.BT/Biocatalysi

. 30 Tomo II (1941-1946) Sexta Época (1939-1966). Anales del Instituto Nacional de Antropología e Historia

Publicación que recopila y difunde cien años de trabajo de la antropología en México (1877-1977), integrada por documentos y manuscritos arqueológicos, antropológicos, históricos, geológicos, botánicos y lingüísticos.- Estudio dental y radiográfico de las mutilaciones dentarias por Samuel Fastlicht. - Análisis de algunos carácteres somáticos de la población de San Miguel Totolapan, Gro. por Johanna Faulhaber. - Teotihuacan: ofrendas de los templos de Quetzalcóatl por Daniel Fernando Rubín de la Borbolla. - Exploraciones arqueológicas en el Totonacapan meridional (Región de Misantla, Ver.) por José García Payón. - El friso de los caciques por Hugo Moedano Köer. - Estudios etnobiológicos, III. Contribuciones mexicanas al conocimiento de la etnobiología del maíz por Manuel Maldonado Koerdell. - Los zapotecos de Choapan, Oaxaca por Julio de la Fuente. - La alimentación tarasca por Silvia Rendón. - Música precortesiana por Jesús C. Romero. - Danzas mexicanas por Raúl G. Guerrero - Notas sobre lugares de Oaxaca, con especial referencia a la toponimia zapoteca por Julio de la Fuente. - Una visita a los indígenas amuzgos de México por George M. Cowan. - Nombres clasificadores, chontales por Margaret Harris. - Palabras y frases de las lenguas tarahumaras y guarijío por Kenneth S. Hilton. - Mapa de Popotla por Alfonso Caso. - La misión del historiador José de J. Núñez y Domínguez en archivos de Europa (1937-1939) por José de J. Núñez y Domínguez. - Noticias sobre algunos archivos hispanoamericanos por María Castelo de Zavala. - La función económica del encomendero en los orígenes del régimen colonial, Nueva España (1525-1531) por José Miranda. - Juan Moritz Rugendas y su colección de pinturas costumbristas por Federico Hernández Serrano

Measurement of charged particle multiplicities and densities in pp collisions at s√=7 TeV in the forward region

Charged particle multiplicities are studied in proton–proton collisions in the forward region at a centre-ofmass energy of √ s = 7 TeV with data collected by the LHCb detector. The forward spectrometer allows access to a kinematic range of 2.0 < η < 4.8 in pseudorapidity, momenta greater than 2 GeV/c and transverse momenta greater than 0.2 GeV/c. The measurements are performed using events with at least one charged particle in the kinematic acceptance. The results are presented as functions of pseudorapidity and transverse momentum and are compared to predictions from several Monte Carlo event generators

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Background: Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial in adults with IgA nephropathy. We report the prespecified interim analysis of the primary proteinuria efficacy endpoint, and safety. Methods: PROTECT is an international, randomised, double-blind, active-controlled study, being conducted in 134 clinical practice sites in 18 countries. The study examines sparsentan versus irbesartan in adults (aged ≥18 years) with biopsy-proven IgA nephropathy and proteinuria of 1·0 g/day or higher despite maximised renin-angiotensin system inhibitor treatment for at least 12 weeks. Participants were randomly assigned in a 1:1 ratio to receive sparsentan 400 mg once daily or irbesartan 300 mg once daily, stratified by estimated glomerular filtration rate at screening (30 to 1·75 g/day). The primary efficacy endpoint was change from baseline to week 36 in urine protein-creatinine ratio based on a 24-h urine sample, assessed using mixed model repeated measures. Treatment-emergent adverse events (TEAEs) were safety endpoints. All endpoints were examined in all participants who received at least one dose of randomised treatment. The study is ongoing and is registered with ClinicalTrials.gov, NCT03762850. Findings: Between Dec 20, 2018, and May 26, 2021, 404 participants were randomly assigned to sparsentan (n=202) or irbesartan (n=202) and received treatment. At week 36, the geometric least squares mean percent change from baseline in urine protein-creatinine ratio was statistically significantly greater in the sparsentan group (-49·8%) than the irbesartan group (-15·1%), resulting in a between-group relative reduction of 41% (least squares mean ratio=0·59; 95% CI 0·51-0·69; p<0·0001). TEAEs with sparsentan were similar to irbesartan. There were no cases of severe oedema, heart failure, hepatotoxicity, or oedema-related discontinuations. Bodyweight changes from baseline were not different between the sparsentan and irbesartan groups. Interpretation: Once-daily treatment with sparsentan produced meaningful reduction in proteinuria compared with irbesartan in adults with IgA nephropathy. Safety of sparsentan was similar to irbesartan. Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term nephroprotective potential of sparsentan. Funding: Travere Therapeutics